Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
lenalidomide
i
Other names:
CDC 5013, CC-5013, CDC-501, CDC-5013, ENMD-0997, IMiD-1, IMiD-3, CC 5013, CDC 5013, ENMD 0997, IMiD3
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(123)
News
Twitter
Trials
Company:
Generic mfg.
Drug class:
TNFα inhibitor
Related drugs:
‹
pomalidomide (15)
onfekafusp alfa (1)
pomalidomide (15)
onfekafusp alfa (1)
›
Associations
(123)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + daratumumab/hyaluronidase
Sensitive: A1 - Approval
lenalidomide + daratumumab / hyaluronidase
Sensitive
:
A1
lenalidomide + daratumumab/hyaluronidase
Sensitive: A1 - Approval
lenalidomide + daratumumab / hyaluronidase
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + elotuzumab
Sensitive: A1 - Approval
lenalidomide + elotuzumab
Sensitive
:
A1
lenalidomide + elotuzumab
Sensitive: A1 - Approval
lenalidomide + elotuzumab
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + daratumumab
Sensitive: A1 - Approval
lenalidomide + daratumumab
Sensitive
:
A1
lenalidomide + daratumumab
Sensitive: A1 - Approval
lenalidomide + daratumumab
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + ixazomib
Sensitive: A1 - Approval
lenalidomide + ixazomib
Sensitive
:
A1
lenalidomide + ixazomib
Sensitive: A1 - Approval
lenalidomide + ixazomib
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
lenalidomide + tafasitamab-cxix
Sensitive: A1 - Approval
lenalidomide + tafasitamab-cxix
Sensitive
:
A1
lenalidomide + tafasitamab-cxix
Sensitive: A1 - Approval
lenalidomide + tafasitamab-cxix
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + carfilzomib
Sensitive: A1 - Approval
lenalidomide + carfilzomib
Sensitive
:
A1
lenalidomide + carfilzomib
Sensitive: A1 - Approval
lenalidomide + carfilzomib
Sensitive
:
A1
Chr del(5q)
Myelodysplastic Syndrome
Chr del(5q)
Myelodysplastic Syndrome
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + bortezomib
Sensitive: A2 - Guideline
lenalidomide + bortezomib
Sensitive
:
A2
lenalidomide + bortezomib
Sensitive: A2 - Guideline
lenalidomide + bortezomib
Sensitive
:
A2
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
lenalidomide + obinutuzumab
Sensitive: A2 - Guideline
lenalidomide + obinutuzumab
Sensitive
:
A2
lenalidomide + obinutuzumab
Sensitive: A2 - Guideline
lenalidomide + obinutuzumab
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
TP53 mutation
Chronic Lymphocytic Leukemia
TP53 mutation
Chronic Lymphocytic Leukemia
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
TP53 mutation
Chronic Lymphocytic Leukemia
TP53 mutation
Chronic Lymphocytic Leukemia
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
CALR mutation
Myelodysplastic Syndrome
CALR mutation
Myelodysplastic Syndrome
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login